#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4. Materials and Methods
1-1	0-2	4.	substance[1]	new[1]	_	_
1-2	3-12	Materials	substance[1]	new[1]	_	_
1-3	13-16	and	_	_	_	_
1-4	17-24	Methods	abstract	new	_	_

#Text=A search was performed of regulatory and scientific literature to identify sources of clinical data to be used to compare the efficacy and safety of BRAFi/MEKi combination therapies for the treatment of BRAF -mutant metastatic melanoma .
2-1	25-26	A	event[3]	new[3]	coref	3-5[17_3]
2-2	27-33	search	event[3]	new[3]	_	_
2-3	34-37	was	_	_	_	_
2-4	38-47	performed	_	_	_	_
2-5	48-50	of	_	_	_	_
2-6	51-61	regulatory	abstract[4]	new[4]	coref	3-6[0_4]
2-7	62-65	and	abstract[4]	new[4]	_	_
2-8	66-76	scientific	abstract[4]	new[4]	_	_
2-9	77-87	literature	abstract[4]	new[4]	_	_
2-10	88-90	to	_	_	_	_
2-11	91-99	identify	_	_	_	_
2-12	100-107	sources	abstract[5]	new[5]	_	_
2-13	108-110	of	abstract[5]	new[5]	_	_
2-14	111-119	clinical	abstract[5]|abstract[6]	new[5]|new[6]	coref	5-37[82_6]
2-15	120-124	data	abstract[5]|abstract[6]	new[5]|new[6]	_	_
2-16	125-127	to	_	_	_	_
2-17	128-130	be	_	_	_	_
2-18	131-135	used	_	_	_	_
2-19	136-138	to	_	_	_	_
2-20	139-146	compare	_	_	_	_
2-21	147-150	the	abstract[7]	new[7]	coref	6-20[0_7]
2-22	151-159	efficacy	abstract[7]	new[7]	_	_
2-23	160-163	and	_	_	_	_
2-24	164-170	safety	abstract[8]	new[8]	coref	14-2[0_8]
2-25	171-173	of	abstract[8]	new[8]	_	_
2-26	174-184	BRAFi/MEKi	abstract[8]|time	new[8]|new	_	_
2-27	185-196	combination	abstract|substance[11]	new|new[11]	coref|coref	19-10[237_0]|19-10[237_0]
2-28	197-206	therapies	substance[11]	new[11]	_	_
2-29	207-210	for	substance[11]	new[11]	_	_
2-30	211-214	the	substance[11]|abstract[12]	new[11]|new[12]	_	_
2-31	215-224	treatment	substance[11]|abstract[12]	new[11]|new[12]	_	_
2-32	225-227	of	substance[11]|abstract[12]	new[11]|new[12]	_	_
2-33	228-232	BRAF	substance[11]|abstract[12]|abstract|abstract[14]	new[11]|new[12]|new|new[14]	coref|coref|coref|coref	4-26[32_0]|4-28[33_14]|4-26[32_0]|4-28[33_14]
2-34	233-240	-mutant	substance[11]|abstract[12]|abstract[14]	new[11]|new[12]|new[14]	_	_
2-35	241-251	metastatic	substance[11]|abstract[12]|abstract[14]	new[11]|new[12]|new[14]	_	_
2-36	252-260	melanoma	substance[11]|abstract[12]|abstract[14]	new[11]|new[12]|new[14]	_	_
2-37	261-262	.	_	_	_	_

#Text=The full details of the literature search are outlined in Table S4 .
3-1	263-266	The	abstract[15]	new[15]	_	_
3-2	267-271	full	abstract[15]	new[15]	_	_
3-3	272-279	details	abstract[15]	new[15]	_	_
3-4	280-282	of	abstract[15]	new[15]	_	_
3-5	283-286	the	abstract[15]|event[17]	new[15]|giv[17]	coref	6-9[86_17]
3-6	287-297	literature	abstract[15]|abstract|event[17]	new[15]|giv|giv[17]	coref	6-11
3-7	298-304	search	abstract[15]|event[17]	new[15]|giv[17]	_	_
3-8	305-308	are	_	_	_	_
3-9	309-317	outlined	_	_	_	_
3-10	318-320	in	_	_	_	_
3-11	321-326	Table	abstract|object[19]	new|new[19]	coref|coref	8-15[105_0]|8-15[105_0]
3-12	327-329	S4	object[19]	new[19]	_	_
3-13	330-331	.	_	_	_	_

#Text=Four phase III studies were identified : coBRIM , a phase III trial of cobimetinib plus vemurafenib versus vemurafenib monotherapy in previously untreated patients with advanced BRAF -mutant melanoma ; COMBI-d , a phase III trial of dabrafenib and trametinib versus dabrafenib monotherapy in previously untreated patients with unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation ; COMBI-v , a phase III trial of dabrafenib plus trametinib versus vemurafenib monotherapy in previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF mutation ; and COLUMBUS Part 1 , a phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib monotherapy in patients with BRAF -mutant melanoma .
4-1	332-336	Four	abstract[20]	new[20]	_	_
4-2	337-342	phase	abstract[20]	new[20]	_	_
4-3	343-346	III	event[21]	new[21]	coref	5-3[72_21]
4-4	347-354	studies	event[21]	new[21]	_	_
4-5	355-359	were	_	_	_	_
4-6	360-370	identified	_	_	_	_
4-7	371-372	:	_	_	_	_
4-8	373-379	coBRIM	organization|abstract[23]	new|new[23]	coref|coref|coref|coref	5-7|10-6[121_23]|5-7|10-6[121_23]
4-9	380-381	,	abstract[23]	new[23]	_	_
4-10	382-383	a	abstract[23]|abstract[24]	new[23]|new[24]	coref	4-33[35_24]
4-11	384-389	phase	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-12	390-393	III	abstract[23]|abstract[24]	new[23]|new[24]	_	_
4-13	394-399	trial	abstract[23]|abstract[25]	new[23]|new[25]	_	_
4-14	400-402	of	abstract[23]|abstract[25]	new[23]|new[25]	_	_
4-15	403-414	cobimetinib	abstract[23]|abstract[25]|abstract|abstract[27]	new[23]|new[25]|new|new[27]	coref|coref|coref|coref	9-21|20-2[241_27]|9-21|20-2[241_27]
4-16	415-419	plus	abstract[23]|abstract[25]|abstract[27]	new[23]|new[25]|new[27]	_	_
4-17	420-431	vemurafenib	abstract[23]|abstract[25]|abstract[27]|abstract[28]	new[23]|new[25]|new[27]|new[28]	coref	4-75[0_28]
4-18	432-438	versus	abstract[23]|abstract[25]|abstract[27]|abstract[28]	new[23]|new[25]|new[27]|new[28]	_	_
4-19	439-450	vemurafenib	abstract[23]|abstract[25]|abstract[27]|abstract[28]|object|abstract[30]	new[23]|new[25]|new[27]|new[28]|new|new[30]	coref|coref	4-75[54_30]|4-75[54_30]
4-20	451-462	monotherapy	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]	new[23]|new[25]|new[27]|new[28]|new[30]	_	_
4-21	463-465	in	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]	new[23]|new[25]|new[27]|new[28]|new[30]	_	_
4-22	466-476	previously	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-23	477-486	untreated	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-24	487-495	patients	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-25	496-500	with	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-26	501-509	advanced	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[32]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[32]	coref	4-58[0_32]
4-27	510-514	BRAF	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[32]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[32]	_	_
4-28	515-522	-mutant	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[33]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[33]	coref	4-54[46_33]
4-29	523-531	melanoma	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[33]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[33]	_	_
4-30	532-533	;	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-31	534-541	COMBI-d	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|organization	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new	coref	6-2[84_0]
4-32	542-543	,	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]	_	_
4-33	544-545	a	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[35]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[35]	_	_
4-34	546-551	phase	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[35]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|giv[35]	_	_
4-35	552-555	III	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]	_	_
4-36	556-561	trial	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]	_	_
4-37	562-564	of	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]	_	_
4-38	565-575	dabrafenib	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new	coref	4-42
4-39	576-579	and	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]	_	_
4-40	580-590	trametinib	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]	coref	4-73[0_38]
4-41	591-597	versus	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]	_	_
4-42	598-608	dabrafenib	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|object|object[40]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|giv|new[40]	coref|coref	4-71|4-71
4-43	609-620	monotherapy	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|object[40]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[40]	_	_
4-44	621-623	in	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]	_	_
4-45	624-634	previously	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]	coref	4-78[55_41]
4-46	635-644	untreated	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]	_	_
4-47	645-653	patients	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]	_	_
4-48	654-658	with	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]	_	_
4-49	659-671	unresectable	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[42]|abstract[43]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[42]|new[43]	coref|coref	8-6[102_43]|8-6[102_43]
4-50	672-677	stage	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[42]|abstract[43]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[42]|new[43]	_	_
4-51	678-682	IIIC	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[42]|abstract[43]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[42]|new[43]	_	_
4-52	683-685	or	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]	_	_
4-53	686-691	stage	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|new	coref	4-82[56_0]
4-54	692-694	IV	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|person|abstract[46]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|new|giv[46]	coref|coref|coref|coref	4-86|4-86[59_46]|4-86|4-86[59_46]
4-55	695-703	melanoma	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]	_	_
4-56	704-708	with	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]	_	_
4-57	709-710	a	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]|abstract[48]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]|new[48]	_	_
4-58	711-715	BRAF	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]|abstract|abstract[48]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]|giv|new[48]	_	_
4-59	716-721	V600E	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]|abstract[48]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]|new[48]	_	_
4-60	722-724	or	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]	_	_
4-61	725-730	V600K	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]|abstract[49]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]|new[49]	coref	4-89[61_49]
4-62	731-739	mutation	abstract[23]|abstract[25]|abstract[27]|abstract[28]|abstract[30]|person[31]|abstract[36]|abstract[38]|person[41]|abstract[43]|abstract[46]|abstract[49]	new[23]|new[25]|new[27]|new[28]|new[30]|new[31]|new[36]|new[38]|new[41]|new[43]|giv[46]|new[49]	_	_
4-63	740-741	;	_	_	_	_
4-64	742-749	COMBI-v	_	_	_	_
4-65	750-751	,	_	_	_	_
4-66	752-753	a	_	_	_	_
4-67	754-759	phase	_	_	_	_
4-68	760-763	III	abstract[50]	new[50]	_	_
4-69	764-769	trial	abstract[50]	new[50]	_	_
4-70	770-772	of	abstract[50]	new[50]	_	_
4-71	773-783	dabrafenib	abstract[50]|abstract	new[50]|giv	coref	9-25
4-72	784-788	plus	abstract[50]	new[50]	_	_
4-73	789-799	trametinib	abstract[50]|abstract	new[50]|giv	coref	9-27
4-74	800-806	versus	abstract[50]	new[50]	_	_
4-75	807-818	vemurafenib	abstract[50]|abstract|abstract[54]	new[50]|giv|giv[54]	coref|coref|coref|coref	4-106|4-108[67_54]|4-106|4-108[67_54]
4-76	819-830	monotherapy	abstract[50]|abstract[54]	new[50]|giv[54]	_	_
4-77	831-833	in	abstract[50]|abstract[54]	new[50]|giv[54]	_	_
4-78	834-844	previously	abstract[50]|abstract[54]|person[55]	new[50]|giv[54]|giv[55]	coref	4-111[68_55]
4-79	845-854	untreated	abstract[50]|abstract[54]|person[55]	new[50]|giv[54]|giv[55]	_	_
4-80	855-863	patients	abstract[50]|abstract[54]|person[55]	new[50]|giv[54]|giv[55]	_	_
4-81	864-868	with	abstract[50]|abstract[54]|person[55]	new[50]|giv[54]|giv[55]	_	_
4-82	869-881	unresectable	abstract[50]|abstract[54]|person[55]|abstract[56]|abstract[57]	new[50]|giv[54]|giv[55]|giv[56]|new[57]	coref|coref	8-6[103_57]|8-6[103_57]
4-83	882-887	stage	abstract[50]|abstract[54]|person[55]|abstract[56]|abstract[57]	new[50]|giv[54]|giv[55]|giv[56]|new[57]	_	_
4-84	888-892	IIIC	abstract[50]|abstract[54]|person[55]|abstract[56]|abstract[57]	new[50]|giv[54]|giv[55]|giv[56]|new[57]	_	_
4-85	893-895	or	abstract[50]|abstract[54]|person[55]|abstract[57]	new[50]|giv[54]|giv[55]|new[57]	_	_
4-86	896-898	IV	abstract[50]|abstract[54]|person[55]|abstract[57]|person|abstract[59]	new[50]|giv[54]|giv[55]|new[57]|giv|giv[59]	coref|coref	4-113[70_59]|4-113[70_59]
4-87	899-907	melanoma	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]	new[50]|giv[54]|giv[55]|new[57]|giv[59]	_	_
4-88	908-912	with	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]	new[50]|giv[54]|giv[55]|new[57]|giv[59]	_	_
4-89	913-917	BRAF	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]|person|abstract[61]	new[50]|giv[54]|giv[55]|new[57]|giv[59]|new|giv[61]	coref|coref	4-113|4-113
4-90	918-926	mutation	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]|abstract[61]	new[50]|giv[54]|giv[55]|new[57]|giv[59]|giv[61]	_	_
4-91	927-928	;	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]	new[50]|giv[54]|giv[55]|new[57]|giv[59]	_	_
4-92	929-932	and	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]	new[50]|giv[54]|giv[55]|new[57]|giv[59]	_	_
4-93	933-941	COLUMBUS	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]|abstract[62]	new[50]|giv[54]|giv[55]|new[57]|giv[59]|new[62]	appos	4-97[63_62]
4-94	942-946	Part	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]|abstract[62]	new[50]|giv[54]|giv[55]|new[57]|giv[59]|new[62]	_	_
4-95	947-948	1	abstract[50]|abstract[54]|person[55]|abstract[57]|abstract[59]|abstract[62]	new[50]|giv[54]|giv[55]|new[57]|giv[59]|new[62]	_	_
4-96	949-950	,	_	_	_	_
4-97	951-952	a	abstract[63]	giv[63]	coref	5-12[76_63]
4-98	953-958	phase	abstract[63]	giv[63]	_	_
4-99	959-962	III	abstract[63]|abstract[64]	giv[63]|new[64]	coref	11-5[151_64]
4-100	963-968	trial	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-101	969-971	of	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-102	972-983	encorafenib	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-103	984-988	plus	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-104	989-1000	binimetinib	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-105	1001-1007	versus	abstract[63]|abstract[64]	giv[63]|new[64]	_	_
4-106	1008-1019	vemurafenib	abstract[63]|abstract[64]|abstract	giv[63]|new[64]|giv	coref	5-18
4-107	1020-1022	or	abstract[63]	giv[63]	_	_
4-108	1023-1034	encorafenib	abstract[63]|abstract|abstract[67]	giv[63]|new|giv[67]	coref|coref	9-29|9-29
4-109	1035-1046	monotherapy	abstract[63]|abstract[67]	giv[63]|giv[67]	_	_
4-110	1047-1049	in	abstract[63]|abstract[67]	giv[63]|giv[67]	_	_
4-111	1050-1058	patients	abstract[63]|abstract[67]|person[68]	giv[63]|giv[67]|giv[68]	_	_
4-112	1059-1063	with	abstract[63]|abstract[67]|person[68]	giv[63]|giv[67]|giv[68]	_	_
4-113	1064-1068	BRAF	abstract[63]|abstract[67]|person[68]|person|abstract[70]	giv[63]|giv[67]|giv[68]|giv|giv[70]	_	_
4-114	1069-1076	-mutant	abstract[63]|abstract[67]|person[68]|abstract[70]	giv[63]|giv[67]|giv[68]|giv[70]	_	_
4-115	1077-1085	melanoma	abstract[63]|abstract[67]|person[68]|abstract[70]	giv[63]|giv[67]|giv[68]|giv[70]	_	_
4-116	1086-1087	.	_	_	_	_

#Text=Three of the identified studies ( coBRIM , COMBI-v , and COLUMBUS Part 1 ) , had vemurafenib 960 mg twice daily ( BID ) as a control arm , and were the chief sources of data for the comparisons presented here .
5-1	1088-1093	Three	quantity[71]	new[71]	_	_
5-2	1094-1096	of	quantity[71]	new[71]	_	_
5-3	1097-1100	the	quantity[71]|event[72]	new[71]|giv[72]	appos	5-7[74_72]
5-4	1101-1111	identified	quantity[71]|event[72]	new[71]|giv[72]	_	_
5-5	1112-1119	studies	quantity[71]|event[72]	new[71]|giv[72]	_	_
5-6	1120-1121	(	_	_	_	_
5-7	1122-1128	coBRIM	object|event[74]	giv|giv[74]	coref|coref|coref|coref	10-6|13-8[174_74]|10-6|13-8[174_74]
5-8	1129-1130	,	event[74]	giv[74]	_	_
5-9	1131-1138	COMBI-v	event[74]|organization	giv[74]|new	coref	7-19
5-10	1139-1140	,	event[74]	giv[74]	_	_
5-11	1141-1144	and	event[74]	giv[74]	_	_
5-12	1145-1153	COLUMBUS	event[74]|abstract[76]	giv[74]|giv[76]	ana	6-14[0_76]
5-13	1154-1158	Part	event[74]|abstract[76]	giv[74]|giv[76]	_	_
5-14	1159-1160	1	event[74]|abstract[76]	giv[74]|giv[76]	_	_
5-15	1161-1162	)	_	_	_	_
5-16	1163-1164	,	_	_	_	_
5-17	1165-1168	had	_	_	_	_
5-18	1169-1180	vemurafenib	abstract|substance[78]	giv|new[78]	coref|coref	6-32|6-32
5-19	1181-1184	960	substance[78]	new[78]	_	_
5-20	1185-1187	mg	substance[78]	new[78]	_	_
5-21	1188-1193	twice	_	_	_	_
5-22	1194-1199	daily	_	_	_	_
5-23	1200-1201	(	_	_	_	_
5-24	1202-1205	BID	quantity	new	_	_
5-25	1206-1207	)	_	_	_	_
5-26	1208-1210	as	_	_	_	_
5-27	1211-1212	a	_	_	_	_
5-28	1213-1220	control	abstract	new	coref	6-33
5-29	1221-1224	arm	_	_	_	_
5-30	1225-1226	,	_	_	_	_
5-31	1227-1230	and	_	_	_	_
5-32	1231-1235	were	_	_	_	_
5-33	1236-1239	the	abstract[81]	new[81]	coref	10-1[119_81]
5-34	1240-1245	chief	abstract[81]	new[81]	_	_
5-35	1246-1253	sources	abstract[81]	new[81]	_	_
5-36	1254-1256	of	abstract[81]	new[81]	_	_
5-37	1257-1261	data	abstract[81]|abstract[82]	new[81]|giv[82]	coref	9-34[117_82]
5-38	1262-1265	for	abstract[81]|abstract[82]	new[81]|giv[82]	_	_
5-39	1266-1269	the	abstract[81]|abstract[82]|abstract[83]	new[81]|giv[82]|new[83]	coref	14-1[182_83]
5-40	1270-1281	comparisons	abstract[81]|abstract[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
5-41	1282-1291	presented	_	_	_	_
5-42	1292-1296	here	_	_	_	_
5-43	1297-1298	.	_	_	_	_

#Text=Although the COMBI-d was identified as part of the initial literature search , it was not included in the efficacy comparison of the cross-trial comparison due to the lack of a vemurafenib control arm .
6-1	1299-1307	Although	_	_	_	_
6-2	1308-1311	the	organization[84]	giv[84]	coref	7-12[0_84]
6-3	1312-1319	COMBI-d	organization[84]	giv[84]	_	_
6-4	1320-1323	was	_	_	_	_
6-5	1324-1334	identified	_	_	_	_
6-6	1335-1337	as	_	_	_	_
6-7	1338-1342	part	_	_	_	_
6-8	1343-1345	of	_	_	_	_
6-9	1346-1349	the	event[86]	giv[86]	_	_
6-10	1350-1357	initial	event[86]	giv[86]	_	_
6-11	1358-1368	literature	abstract|event[86]	giv|giv[86]	_	_
6-12	1369-1375	search	event[86]	giv[86]	_	_
6-13	1376-1377	,	_	_	_	_
6-14	1378-1380	it	abstract	giv	_	_
6-15	1381-1384	was	_	_	_	_
6-16	1385-1388	not	_	_	_	_
6-17	1389-1397	included	_	_	_	_
6-18	1398-1400	in	_	_	_	_
6-19	1401-1404	the	abstract[89]	new[89]	coref	9-7[107_89]
6-20	1405-1413	efficacy	abstract|abstract[89]	giv|new[89]	coref	12-2
6-21	1414-1424	comparison	abstract[89]	new[89]	_	_
6-22	1425-1427	of	abstract[89]	new[89]	_	_
6-23	1428-1431	the	abstract[89]|event[90]	new[89]|new[90]	_	_
6-24	1432-1443	cross-trial	abstract[89]|event[90]	new[89]|new[90]	_	_
6-25	1444-1454	comparison	abstract[89]|event[90]	new[89]|new[90]	_	_
6-26	1455-1458	due	_	_	_	_
6-27	1459-1461	to	_	_	_	_
6-28	1462-1465	the	abstract[91]	new[91]	ana	7-1[0_91]
6-29	1466-1470	lack	abstract[91]	new[91]	_	_
6-30	1471-1473	of	abstract[91]	new[91]	_	_
6-31	1474-1475	a	abstract[91]|object[94]	new[91]|new[94]	_	_
6-32	1476-1487	vemurafenib	abstract[91]|abstract|object[94]	new[91]|giv|new[94]	coref	9-23
6-33	1488-1495	control	abstract[91]|abstract|object[94]	new[91]|giv|new[94]	_	_
6-34	1496-1499	arm	abstract[91]|object[94]	new[91]|new[94]	_	_
6-35	1500-1501	.	_	_	_	_

#Text=It should be noted , however , that the outcomes in COMBI-d were substantially similar to those in COMBI-v .
7-1	1502-1504	It	abstract	giv	ana	7-17[98_0]
7-2	1505-1511	should	_	_	_	_
7-3	1512-1514	be	_	_	_	_
7-4	1515-1520	noted	_	_	_	_
7-5	1521-1522	,	_	_	_	_
7-6	1523-1530	however	_	_	_	_
7-7	1531-1532	,	_	_	_	_
7-8	1533-1537	that	_	_	_	_
7-9	1538-1541	the	abstract[96]	new[96]	coref	12-1[159_96]
7-10	1542-1550	outcomes	abstract[96]	new[96]	_	_
7-11	1551-1553	in	abstract[96]	new[96]	_	_
7-12	1554-1561	COMBI-d	abstract[96]|abstract	new[96]|giv	coref	19-16
7-13	1562-1566	were	_	_	_	_
7-14	1567-1580	substantially	_	_	_	_
7-15	1581-1588	similar	_	_	_	_
7-16	1589-1591	to	_	_	_	_
7-17	1592-1597	those	abstract[98]	giv[98]	_	_
7-18	1598-1600	in	abstract[98]	giv[98]	_	_
7-19	1601-1608	COMBI-v	abstract[98]|abstract	giv[98]|giv	coref	10-8
7-20	1609-1610	.	_	_	_	_

#Text=The key design features of the three included phase III trials are summarized in Table 5 .
8-1	1611-1614	The	abstract[101]	new[101]	_	_
8-2	1615-1618	key	abstract[101]	new[101]	_	_
8-3	1619-1625	design	abstract|abstract[101]	new|new[101]	_	_
8-4	1626-1634	features	abstract[101]	new[101]	_	_
8-5	1635-1637	of	abstract[101]	new[101]	_	_
8-6	1638-1641	the	abstract[101]|abstract[102]|abstract[103]	new[101]|giv[102]|giv[103]	_	_
8-7	1642-1647	three	abstract[101]|abstract[102]|abstract[103]	new[101]|giv[102]|giv[103]	_	_
8-8	1648-1656	included	abstract[101]|abstract[102]|abstract[103]	new[101]|giv[102]|giv[103]	_	_
8-9	1657-1662	phase	abstract[101]|abstract[102]|abstract[103]	new[101]|giv[102]|giv[103]	_	_
8-10	1663-1666	III	abstract[101]|abstract[103]|abstract[104]	new[101]|giv[103]|new[104]	coref	10-5[123_104]
8-11	1667-1673	trials	abstract[101]|abstract[103]|abstract[104]	new[101]|giv[103]|new[104]	_	_
8-12	1674-1677	are	_	_	_	_
8-13	1678-1688	summarized	_	_	_	_
8-14	1689-1691	in	_	_	_	_
8-15	1692-1697	Table	abstract[105]	giv[105]	coref	10-46[0_105]
8-16	1698-1699	5	abstract[105]	giv[105]	_	_
8-17	1700-1701	.	_	_	_	_

#Text=To assist with the completeness of the cross-trial comparison , medical information requests were made to the registered sponsor of cobimetinib , vemurafenib , dabrafenib , trametinib , encorafenib , or binimetinib if any missing data were identified .
9-1	1702-1704	To	_	_	_	_
9-2	1705-1711	assist	_	_	_	_
9-3	1712-1716	with	_	_	_	_
9-4	1717-1720	the	abstract[106]	new[106]	_	_
9-5	1721-1733	completeness	abstract[106]	new[106]	_	_
9-6	1734-1736	of	abstract[106]	new[106]	_	_
9-7	1737-1740	the	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
9-8	1741-1752	cross-trial	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
9-9	1753-1763	comparison	abstract[106]|abstract[107]	new[106]|giv[107]	_	_
9-10	1764-1765	,	_	_	_	_
9-11	1766-1773	medical	abstract[109]	new[109]	_	_
9-12	1774-1785	information	abstract|abstract[109]	new|new[109]	coref	10-39[137_0]
9-13	1786-1794	requests	abstract[109]	new[109]	_	_
9-14	1795-1799	were	_	_	_	_
9-15	1800-1804	made	_	_	_	_
9-16	1805-1807	to	_	_	_	_
9-17	1808-1811	the	person[110]	new[110]	_	_
9-18	1812-1822	registered	person[110]	new[110]	_	_
9-19	1823-1830	sponsor	person[110]	new[110]	_	_
9-20	1831-1833	of	person[110]	new[110]	_	_
9-21	1834-1845	cobimetinib	person[110]|object	new[110]|giv	coref	20-2[240_0]
9-22	1846-1847	,	person[110]	new[110]	_	_
9-23	1848-1859	vemurafenib	person[110]|abstract	new[110]|giv	coref	20-5
9-24	1860-1861	,	person[110]	new[110]	_	_
9-25	1862-1872	dabrafenib	person[110]|object	new[110]|giv	coref	19-7[236_0]
9-26	1873-1874	,	person[110]	new[110]	_	_
9-27	1875-1885	trametinib	person[110]|abstract	new[110]|giv	_	_
9-28	1886-1887	,	person[110]	new[110]	_	_
9-29	1888-1899	encorafenib	person[110]|substance	new[110]|giv	coref	21-16[250_0]
9-30	1900-1901	,	person[110]	new[110]	_	_
9-31	1902-1904	or	person[110]	new[110]	_	_
9-32	1905-1916	binimetinib	person[110]|object	new[110]|new	coref	21-19
9-33	1917-1919	if	_	_	_	_
9-34	1920-1923	any	abstract[117]	giv[117]	coref	10-16[125_117]
9-35	1924-1931	missing	abstract[117]	giv[117]	_	_
9-36	1932-1936	data	abstract[117]	giv[117]	_	_
9-37	1937-1941	were	_	_	_	_
9-38	1942-1952	identified	_	_	_	_
9-39	1953-1954	.	_	_	_	_

#Text=The data sources for the coBRIM and COMBI-v trials included primary and secondary publications of data , European public assessment reports ( EPAR ) , U.S. Food and Drug Administration ( FDA ) medical review documents , and the current U.S. prescribing information ( see Table S5 , which illustrates the data sources and cutoff dates for COMBI-v , coBRIM , and COLUMBUS trials ) .
10-1	1955-1958	The	abstract[119]	giv[119]	coref	10-51[141_119]
10-2	1959-1963	data	abstract|abstract[119]	new|giv[119]	_	_
10-3	1964-1971	sources	abstract[119]	giv[119]	_	_
10-4	1972-1975	for	abstract[119]	giv[119]	_	_
10-5	1976-1979	the	abstract[119]|abstract[123]	giv[119]|giv[123]	coref	10-63[147_123]
10-6	1980-1986	coBRIM	abstract[119]|organization|abstract[121]|abstract[123]	giv[119]|giv|giv[121]|giv[123]	coref|coref|coref|coref	10-60|17-2[220_121]|10-60|17-2[220_121]
10-7	1987-1990	and	abstract[119]|abstract[121]|abstract[123]	giv[119]|giv[121]|giv[123]	_	_
10-8	1991-1998	COMBI-v	abstract[119]|abstract[121]|event|abstract[123]	giv[119]|giv[121]|giv|giv[123]	coref	10-58
10-9	1999-2005	trials	abstract[119]|abstract[123]	giv[119]|giv[123]	_	_
10-10	2006-2014	included	_	_	_	_
10-11	2015-2022	primary	abstract[124]	new[124]	_	_
10-12	2023-2026	and	abstract[124]	new[124]	_	_
10-13	2027-2036	secondary	abstract[124]	new[124]	_	_
10-14	2037-2049	publications	abstract[124]	new[124]	_	_
10-15	2050-2052	of	abstract[124]	new[124]	_	_
10-16	2053-2057	data	abstract[124]|abstract[125]	new[124]|giv[125]	coref	10-52[0_125]
10-17	2058-2059	,	abstract[124]|abstract[125]	new[124]|giv[125]	_	_
10-18	2060-2068	European	abstract[124]|abstract[125]|abstract[127]	new[124]|giv[125]|new[127]	_	_
10-19	2069-2075	public	abstract[124]|abstract[125]|abstract[127]	new[124]|giv[125]|new[127]	_	_
10-20	2076-2086	assessment	abstract[124]|abstract[125]|abstract|abstract[127]	new[124]|giv[125]|new|new[127]	coref	12-22[169_0]
10-21	2087-2094	reports	abstract[124]|abstract[125]|abstract[127]	new[124]|giv[125]|new[127]	_	_
10-22	2095-2096	(	_	_	_	_
10-23	2097-2101	EPAR	organization	new	_	_
10-24	2102-2103	)	_	_	_	_
10-25	2104-2105	,	_	_	_	_
10-26	2106-2110	U.S.	place|object[130]	new|new[130]	coref|coref	10-41|10-41
10-27	2111-2115	Food	object[130]	new[130]	_	_
10-28	2116-2119	and	_	_	_	_
10-29	2120-2124	Drug	organization[131]	new[131]	appos	10-32[0_131]
10-30	2125-2139	Administration	organization[131]	new[131]	_	_
10-31	2140-2141	(	_	_	_	_
10-32	2142-2145	FDA	organization	giv	_	_
10-33	2146-2147	)	_	_	_	_
10-34	2148-2155	medical	abstract[133]|object[134]	new[133]|new[134]	_	_
10-35	2156-2162	review	abstract[133]|object[134]	new[133]|new[134]	_	_
10-36	2163-2172	documents	object[134]	new[134]	_	_
10-37	2173-2174	,	_	_	_	_
10-38	2175-2178	and	_	_	_	_
10-39	2179-2182	the	abstract[137]	giv[137]	coref	11-13[154_137]
10-40	2183-2190	current	abstract[137]	giv[137]	_	_
10-41	2191-2195	U.S.	place|abstract[137]	giv|giv[137]	coref	11-13
10-42	2196-2207	prescribing	person|abstract[137]	new|giv[137]	_	_
10-43	2208-2219	information	abstract[137]	giv[137]	_	_
10-44	2220-2221	(	_	_	_	_
10-45	2222-2225	see	_	_	_	_
10-46	2226-2231	Table	abstract|object[139]	giv|new[139]	_	_
10-47	2232-2234	S5	object[139]	new[139]	_	_
10-48	2235-2236	,	_	_	_	_
10-49	2237-2242	which	_	_	_	_
10-50	2243-2254	illustrates	_	_	_	_
10-51	2255-2258	the	abstract[141]	giv[141]	coref	11-1[149_141]
10-52	2259-2263	data	abstract|abstract[141]	giv|giv[141]	coref	11-2
10-53	2264-2271	sources	abstract[141]	giv[141]	_	_
10-54	2272-2275	and	abstract[141]	giv[141]	_	_
10-55	2276-2282	cutoff	abstract[141]|abstract|time[143]	giv[141]|new|new[143]	_	_
10-56	2283-2288	dates	abstract[141]|time[143]	giv[141]|new[143]	_	_
10-57	2289-2292	for	abstract[141]|time[143]	giv[141]|new[143]	_	_
10-58	2293-2300	COMBI-v	abstract[141]|time[143]|abstract	giv[141]|new[143]|giv	coref	17-4
10-59	2301-2302	,	abstract[141]|time[143]	giv[141]|new[143]	_	_
10-60	2303-2309	coBRIM	abstract[141]|time[143]|object	giv[141]|new[143]|giv	coref	17-2
10-61	2310-2311	,	abstract[141]|time[143]	giv[141]|new[143]	_	_
10-62	2312-2315	and	abstract[141]|time[143]	giv[141]|new[143]	_	_
10-63	2316-2324	COLUMBUS	abstract[141]|time[143]|place|abstract[147]	giv[141]|new[143]|new|giv[147]	coref|coref|coref|coref	11-6|17-1[222_147]|11-6|17-1[222_147]
10-64	2325-2331	trials	abstract[141]|time[143]|abstract[147]	giv[141]|new[143]|giv[147]	_	_
10-65	2332-2333	)	_	_	_	_
10-66	2334-2335	.	_	_	_	_

#Text=The data sources for the COLUMBUS trial include a primary publication , U.S. prescribing information , and Array BioPharma data on file .
11-1	2336-2339	The	abstract[149]	giv[149]	_	_
11-2	2340-2344	data	abstract|abstract[149]	giv|giv[149]	coref	11-18[156_0]
11-3	2345-2352	sources	abstract[149]	giv[149]	_	_
11-4	2353-2356	for	abstract[149]	giv[149]	_	_
11-5	2357-2360	the	abstract[149]|abstract[151]	giv[149]|giv[151]	coref	17-11[225_151]
11-6	2361-2369	COLUMBUS	abstract[149]|place|abstract[151]	giv[149]|giv|giv[151]	coref	17-12
11-7	2370-2375	trial	abstract[149]|abstract[151]	giv[149]|giv[151]	_	_
11-8	2376-2383	include	_	_	_	_
11-9	2384-2385	a	abstract[152]	new[152]	_	_
11-10	2386-2393	primary	abstract[152]	new[152]	_	_
11-11	2394-2405	publication	abstract[152]	new[152]	_	_
11-12	2406-2407	,	_	_	_	_
11-13	2408-2412	U.S.	place|abstract[154]	giv|giv[154]	coref|coref	18-13|18-13
11-14	2413-2424	prescribing	abstract[154]	giv[154]	_	_
11-15	2425-2436	information	abstract[154]	giv[154]	_	_
11-16	2437-2438	,	_	_	_	_
11-17	2439-2442	and	_	_	_	_
11-18	2443-2448	Array	organization[155]|abstract[156]	new[155]|giv[156]	coref|coref	14-36[192_156]|14-36[192_156]
11-19	2449-2458	BioPharma	organization[155]|abstract[156]	new[155]|giv[156]	_	_
11-20	2459-2463	data	abstract[156]	giv[156]	_	_
11-21	2464-2466	on	abstract[156]	giv[156]	_	_
11-22	2467-2471	file	abstract[156]|object	giv[156]|new	_	_
11-23	2472-2473	.	_	_	_	_

#Text=The efficacy outcomes presented are PFS , objective response rate ( ORR ) , duration of response ( DOR ) per investigator assessment , and OS .
12-1	2474-2477	The	abstract[159]	giv[159]	coref	12-6[160_159]
12-2	2478-2486	efficacy	abstract|abstract[159]	giv|giv[159]	_	_
12-3	2487-2495	outcomes	abstract[159]	giv[159]	_	_
12-4	2496-2505	presented	_	_	_	_
12-5	2506-2509	are	_	_	_	_
12-6	2510-2513	PFS	abstract[160]	giv[160]	_	_
12-7	2514-2515	,	abstract[160]	giv[160]	_	_
12-8	2516-2525	objective	abstract[160]|abstract|abstract[163]	giv[160]|new|new[163]	appos|appos	12-12[0_163]|12-12[0_163]
12-9	2526-2534	response	abstract[160]|event|abstract[163]	giv[160]|new|new[163]	coref	12-17
12-10	2535-2539	rate	abstract[160]|abstract[163]	giv[160]|new[163]	_	_
12-11	2540-2541	(	abstract[160]	giv[160]	_	_
12-12	2542-2545	ORR	abstract[160]|abstract	giv[160]|giv	_	_
12-13	2546-2547	)	abstract[160]	giv[160]	_	_
12-14	2548-2549	,	abstract[160]	giv[160]	_	_
12-15	2550-2558	duration	abstract[160]|abstract[165]	giv[160]|new[165]	_	_
12-16	2559-2561	of	abstract[160]|abstract[165]	giv[160]|new[165]	_	_
12-17	2562-2570	response	abstract[160]|abstract[165]|event	giv[160]|new[165]|giv	appos	12-19
12-18	2571-2572	(	_	_	_	_
12-19	2573-2576	DOR	event	giv	coref	13-4[173_0]
12-20	2577-2578	)	_	_	_	_
12-21	2579-2582	per	_	_	_	_
12-22	2583-2595	investigator	person|abstract[169]	new|giv[169]	coref|coref	13-14[0_169]|13-14[0_169]
12-23	2596-2606	assessment	abstract[169]	giv[169]	_	_
12-24	2607-2608	,	_	_	_	_
12-25	2609-2612	and	_	_	_	_
12-26	2613-2615	OS	abstract	new	_	_
12-27	2616-2617	.	_	_	_	_

#Text=The assessments of the tumor response across the studies were performed using Response Evaluation Criteria in Solid Tumors ( RECIST ) version 1.1 .
13-1	2618-2621	The	abstract[171]	new[171]	_	_
13-2	2622-2633	assessments	abstract[171]	new[171]	_	_
13-3	2634-2636	of	abstract[171]	new[171]	_	_
13-4	2637-2640	the	abstract[171]|event[173]	new[171]|giv[173]	coref	13-13[0_173]
13-5	2641-2646	tumor	abstract[171]|abstract|event[173]	new[171]|new|giv[173]	_	_
13-6	2647-2655	response	abstract[171]|event[173]	new[171]|giv[173]	_	_
13-7	2656-2662	across	abstract[171]|event[173]	new[171]|giv[173]	_	_
13-8	2663-2666	the	abstract[171]|event[173]|event[174]	new[171]|giv[173]|giv[174]	coref	16-1[210_174]
13-9	2667-2674	studies	abstract[171]|event[173]|event[174]	new[171]|giv[173]|giv[174]	_	_
13-10	2675-2679	were	_	_	_	_
13-11	2680-2689	performed	_	_	_	_
13-12	2690-2695	using	_	_	_	_
13-13	2696-2704	Response	event|abstract[177]	giv|new[177]	coref|coref|coref|coref	14-7[183_0]|16-11[214_177]|14-7[183_0]|16-11[214_177]
13-14	2705-2715	Evaluation	abstract|abstract[177]	giv|new[177]	_	_
13-15	2716-2724	Criteria	abstract[177]	new[177]	_	_
13-16	2725-2727	in	abstract[177]	new[177]	_	_
13-17	2728-2733	Solid	abstract[177]|place[178]|abstract[180]	new[177]|new[178]|new[180]	_	_
13-18	2734-2740	Tumors	abstract[177]|place[178]|abstract[180]	new[177]|new[178]|new[180]	_	_
13-19	2741-2742	(	abstract[177]|abstract[180]	new[177]|new[180]	_	_
13-20	2743-2749	RECIST	abstract[177]|abstract|abstract[180]	new[177]|new|new[180]	_	_
13-21	2750-2751	)	abstract[177]|abstract[180]	new[177]|new[180]	_	_
13-22	2752-2759	version	abstract[177]|abstract[180]	new[177]|new[180]	_	_
13-23	2760-2763	1.1	abstract[177]|abstract[180]	new[177]|new[180]	_	_
13-24	2764-2765	.	_	_	_	_

#Text=The safety comparisons were made using the adverse event ( any untoward medical occurrence regardless of causal relationship ) and adverse drug reaction ( noxious and unintended responses with at least a reasonable possibility of a causal relationship ) data .
14-1	2766-2769	The	abstract[182]	giv[182]	_	_
14-2	2770-2776	safety	abstract|abstract[182]	giv|giv[182]	_	_
14-3	2777-2788	comparisons	abstract[182]	giv[182]	_	_
14-4	2789-2793	were	_	_	_	_
14-5	2794-2798	made	_	_	_	_
14-6	2799-2804	using	_	_	_	_
14-7	2805-2808	the	event[183]	giv[183]	coref	15-3[0_183]
14-8	2809-2816	adverse	event[183]	giv[183]	_	_
14-9	2817-2822	event	event[183]	giv[183]	_	_
14-10	2823-2824	(	_	_	_	_
14-11	2825-2828	any	_	_	_	_
14-12	2829-2837	untoward	_	_	_	_
14-13	2838-2845	medical	_	_	_	_
14-14	2846-2856	occurrence	abstract	new	_	_
14-15	2857-2867	regardless	_	_	_	_
14-16	2868-2870	of	_	_	_	_
14-17	2871-2877	causal	abstract[185]	new[185]	coref	14-36[191_185]
14-18	2878-2890	relationship	abstract[185]	new[185]	_	_
14-19	2891-2892	)	_	_	_	_
14-20	2893-2896	and	_	_	_	_
14-21	2897-2904	adverse	event[187]	new[187]	appos	14-24[189_187]
14-22	2905-2909	drug	substance|event[187]	new|new[187]	coref	18-8
14-23	2910-2918	reaction	event[187]	new[187]	_	_
14-24	2919-2920	(	event[189]	giv[189]	_	_
14-25	2921-2928	noxious	abstract[188]|event[189]	new[188]|giv[189]	_	_
14-26	2929-2932	and	abstract[188]|event[189]	new[188]|giv[189]	_	_
14-27	2933-2943	unintended	abstract[188]|event[189]	new[188]|giv[189]	_	_
14-28	2944-2953	responses	abstract[188]|event[189]	new[188]|giv[189]	_	_
14-29	2954-2958	with	event[189]	giv[189]	_	_
14-30	2959-2961	at	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-31	2962-2967	least	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-32	2968-2969	a	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-33	2970-2980	reasonable	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-34	2981-2992	possibility	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-35	2993-2995	of	event[189]|abstract[190]	giv[189]|new[190]	_	_
14-36	2996-2997	a	event[189]|abstract[190]|abstract[191]|abstract[192]	giv[189]|new[190]|giv[191]|giv[192]	coref|coref	15-1[194_192]|15-1[194_192]
14-37	2998-3004	causal	event[189]|abstract[190]|abstract[191]|abstract[192]	giv[189]|new[190]|giv[191]|giv[192]	_	_
14-38	3005-3017	relationship	event[189]|abstract[190]|abstract[191]|abstract[192]	giv[189]|new[190]|giv[191]|giv[192]	_	_
14-39	3018-3019	)	event[189]|abstract[190]|abstract[192]	giv[189]|new[190]|giv[192]	_	_
14-40	3020-3024	data	event[189]|abstract[190]|abstract[192]	giv[189]|new[190]|giv[192]	_	_
14-41	3025-3026	.	_	_	_	_

#Text=The adverse event data included the overall summaries ( comprising all-grade , serious , and grade 3/4 AEs , and AEs leading to death , dose interruption/modification , and discontinuation ) and the incidence of specific all-grade and grade 3/4 AEs by individual preferred terms per the MedDRA dictionary .
15-1	3027-3030	The	abstract[194]	giv[194]	coref	18-5[229_194]
15-2	3031-3038	adverse	abstract[194]	giv[194]	_	_
15-3	3039-3044	event	event|abstract[194]	giv|giv[194]	coref	19-4
15-4	3045-3049	data	abstract[194]	giv[194]	_	_
15-5	3050-3058	included	_	_	_	_
15-6	3059-3062	the	object[195]	new[195]	_	_
15-7	3063-3070	overall	object[195]	new[195]	_	_
15-8	3071-3080	summaries	object[195]	new[195]	_	_
15-9	3081-3082	(	_	_	_	_
15-10	3083-3093	comprising	_	_	_	_
15-11	3094-3103	all-grade	_	_	_	_
15-12	3104-3105	,	_	_	_	_
15-13	3106-3113	serious	_	_	_	_
15-14	3114-3115	,	_	_	_	_
15-15	3116-3119	and	_	_	_	_
15-16	3120-3125	grade	abstract[196]	new[196]	coref	15-39[0_196]
15-17	3126-3129	3/4	abstract[196]|abstract[197]	new[196]|new[197]	coref	15-21[0_197]
15-18	3130-3133	AEs	abstract[196]|abstract[197]	new[196]|new[197]	_	_
15-19	3134-3135	,	_	_	_	_
15-20	3136-3139	and	_	_	_	_
15-21	3140-3143	AEs	abstract	giv	coref	15-40[206_0]
15-22	3144-3151	leading	_	_	_	_
15-23	3152-3154	to	_	_	_	_
15-24	3155-3160	death	event	new	_	_
15-25	3161-3162	,	_	_	_	_
15-26	3163-3167	dose	quantity|abstract[201]	new|new[201]	_	_
15-27	3168-3193	interruption/modification	abstract[201]	new[201]	_	_
15-28	3194-3195	,	_	_	_	_
15-29	3196-3199	and	_	_	_	_
15-30	3200-3215	discontinuation	abstract	new	_	_
15-31	3216-3217	)	_	_	_	_
15-32	3218-3221	and	_	_	_	_
15-33	3222-3225	the	abstract[203]	new[203]	_	_
15-34	3226-3235	incidence	abstract[203]	new[203]	_	_
15-35	3236-3238	of	abstract[203]	new[203]	_	_
15-36	3239-3247	specific	abstract[203]|abstract[204]	new[203]|new[204]	_	_
15-37	3248-3257	all-grade	abstract[203]|abstract[204]	new[203]|new[204]	_	_
15-38	3258-3261	and	abstract[203]	new[203]	_	_
15-39	3262-3267	grade	abstract[203]|abstract	new[203]|giv	_	_
15-40	3268-3271	3/4	abstract[203]|abstract[206]	new[203]|giv[206]	_	_
15-41	3272-3275	AEs	abstract[203]|abstract[206]	new[203]|giv[206]	_	_
15-42	3276-3278	by	abstract[203]	new[203]	_	_
15-43	3279-3289	individual	abstract[203]|abstract[207]	new[203]|new[207]	_	_
15-44	3290-3299	preferred	abstract[203]|abstract[207]	new[203]|new[207]	_	_
15-45	3300-3305	terms	abstract[203]|abstract[207]	new[203]|new[207]	_	_
15-46	3306-3309	per	abstract[203]|abstract[207]	new[203]|new[207]	_	_
15-47	3310-3313	the	abstract[203]|abstract[207]|object[209]	new[203]|new[207]|new[209]	_	_
15-48	3314-3320	MedDRA	abstract[203]|abstract[207]|person|object[209]	new[203]|new[207]|new|new[209]	_	_
15-49	3321-3331	dictionary	abstract[203]|abstract[207]|object[209]	new[203]|new[207]|new[209]	_	_
15-50	3332-3333	.	_	_	_	_

#Text=All studies utilized the National Cancer Institute ( NCI ) Common Terminology Criteria for Adverse Events ( CTCAE ) to assess severity .
16-1	3334-3337	All	event[210]	giv[210]	_	_
16-2	3338-3345	studies	event[210]	giv[210]	_	_
16-3	3346-3354	utilized	_	_	_	_
16-4	3355-3358	the	organization[211]	new[211]	appos	16-9[0_211]
16-5	3359-3367	National	organization[211]	new[211]	_	_
16-6	3368-3374	Cancer	organization[211]	new[211]	_	_
16-7	3375-3384	Institute	organization[211]	new[211]	_	_
16-8	3385-3386	(	_	_	_	_
16-9	3387-3390	NCI	organization	giv	_	_
16-10	3391-3392	)	_	_	_	_
16-11	3393-3399	Common	abstract[214]	giv[214]	_	_
16-12	3400-3411	Terminology	abstract|abstract[214]	new|giv[214]	_	_
16-13	3412-3420	Criteria	abstract[214]	giv[214]	_	_
16-14	3421-3424	for	abstract[214]	giv[214]	_	_
16-15	3425-3432	Adverse	abstract[214]|person|abstract[216]	giv[214]|new|new[216]	appos|appos	16-18[0_216]|16-18[0_216]
16-16	3433-3439	Events	abstract[214]|abstract[216]	giv[214]|new[216]	_	_
16-17	3440-3441	(	_	_	_	_
16-18	3442-3447	CTCAE	abstract	giv	_	_
16-19	3448-3449	)	_	_	_	_
16-20	3450-3452	to	_	_	_	_
16-21	3453-3459	assess	_	_	_	_
16-22	3460-3468	severity	abstract	new	_	_
16-23	3469-3470	.	_	_	_	_

#Text=The coBRIM and COMBI-v trials used version 4.0 , whereas the COLUMBUS trial used version 4.03 .
17-1	3471-3474	The	abstract[222]	giv[222]	_	_
17-2	3475-3481	coBRIM	object|abstract[220]|abstract[222]	giv|giv[220]|giv[222]	coref|coref	20-9|20-9
17-3	3482-3485	and	abstract[220]|abstract[222]	giv[220]|giv[222]	_	_
17-4	3486-3493	COMBI-v	abstract[220]|organization|abstract[222]	giv[220]|giv|giv[222]	_	_
17-5	3494-3500	trials	abstract[222]	giv[222]	_	_
17-6	3501-3505	used	_	_	_	_
17-7	3506-3513	version	abstract[223]	new[223]	coref	17-15[0_223]
17-8	3514-3517	4.0	abstract[223]	new[223]	_	_
17-9	3518-3519	,	_	_	_	_
17-10	3520-3527	whereas	_	_	_	_
17-11	3528-3531	the	abstract[225]	giv[225]	coref	19-15[239_225]
17-12	3532-3540	COLUMBUS	organization|abstract[225]	giv|giv[225]	coref	21-2
17-13	3541-3546	trial	abstract[225]	giv[225]	_	_
17-14	3547-3551	used	_	_	_	_
17-15	3552-3559	version	abstract	giv	_	_
17-16	3560-3564	4.03	quantity	new	_	_
17-17	3565-3566	.	_	_	_	_

#Text=The primary source of data on adverse drug reactions was the available U.S. prescribing information .
18-1	3567-3570	The	abstract[228]	new[228]	coref	18-11[233_228]
18-2	3571-3578	primary	abstract[228]	new[228]	_	_
18-3	3579-3585	source	abstract[228]	new[228]	_	_
18-4	3586-3588	of	abstract[228]	new[228]	_	_
18-5	3589-3593	data	abstract[228]|abstract[229]	new[228]|giv[229]	coref	19-1[235_229]
18-6	3594-3596	on	abstract[228]|abstract[229]	new[228]|giv[229]	_	_
18-7	3597-3604	adverse	abstract[228]|abstract[229]|event[231]	new[228]|giv[229]|new[231]	_	_
18-8	3605-3609	drug	abstract[228]|abstract[229]|substance|event[231]	new[228]|giv[229]|giv|new[231]	_	_
18-9	3610-3619	reactions	abstract[228]|abstract[229]|event[231]	new[228]|giv[229]|new[231]	_	_
18-10	3620-3623	was	_	_	_	_
18-11	3624-3627	the	abstract[233]	giv[233]	coref	21-10[248_233]
18-12	3628-3637	available	abstract[233]	giv[233]	_	_
18-13	3638-3642	U.S.	place|abstract[233]	giv|giv[233]	_	_
18-14	3643-3654	prescribing	abstract[233]	giv[233]	_	_
18-15	3655-3666	information	abstract[233]	giv[233]	_	_
18-16	3667-3668	.	_	_	_	_

#Text=The additional adverse event data for the dabrafenib plus trametinib combination was derived from the COMBI-d trial .
19-1	3669-3672	The	abstract[235]	giv[235]	_	_
19-2	3673-3683	additional	abstract[235]	giv[235]	_	_
19-3	3684-3691	adverse	abstract[235]	giv[235]	_	_
19-4	3692-3697	event	event|abstract[235]	giv|giv[235]	_	_
19-5	3698-3702	data	abstract[235]	giv[235]	_	_
19-6	3703-3706	for	abstract[235]	giv[235]	_	_
19-7	3707-3710	the	abstract[235]|abstract[236]	giv[235]|giv[236]	_	_
19-8	3711-3721	dabrafenib	abstract[235]|abstract[236]	giv[235]|giv[236]	_	_
19-9	3722-3726	plus	abstract[235]	giv[235]	_	_
19-10	3727-3737	trametinib	abstract[235]|abstract[237]	giv[235]|giv[237]	coref	20-5[243_237]
19-11	3738-3749	combination	abstract[235]|abstract[237]	giv[235]|giv[237]	_	_
19-12	3750-3753	was	_	_	_	_
19-13	3754-3761	derived	_	_	_	_
19-14	3762-3766	from	_	_	_	_
19-15	3767-3770	the	abstract[239]	giv[239]	coref	20-8[245_239]
19-16	3771-3778	COMBI-d	abstract|abstract[239]	giv|giv[239]	_	_
19-17	3779-3784	trial	abstract[239]	giv[239]	_	_
19-18	3785-3786	.	_	_	_	_

#Text=For the cobimetinib plus vemurafenib combination , the coBRIM trial was utilized .
20-1	3787-3790	For	_	_	_	_
20-2	3791-3794	the	abstract[240]|abstract[241]	giv[240]|giv[241]	_	_
20-3	3795-3806	cobimetinib	abstract[240]|abstract[241]	giv[240]|giv[241]	_	_
20-4	3807-3811	plus	abstract[241]	giv[241]	_	_
20-5	3812-3823	vemurafenib	abstract[241]|abstract|abstract[243]	giv[241]|giv|giv[243]	coref|coref	21-19[252_243]|21-19[252_243]
20-6	3824-3835	combination	abstract[241]|abstract[243]	giv[241]|giv[243]	_	_
20-7	3836-3837	,	_	_	_	_
20-8	3838-3841	the	abstract[245]	giv[245]	_	_
20-9	3842-3848	coBRIM	abstract|abstract[245]	giv|giv[245]	_	_
20-10	3849-3854	trial	abstract[245]	giv[245]	_	_
20-11	3855-3858	was	_	_	_	_
20-12	3859-3867	utilized	_	_	_	_
20-13	3868-3869	.	_	_	_	_

#Text=The COLUMBUS study was utilized as a source of additional information for adverse events for the encorafenib plus binimetinib combination .
21-1	3870-3873	The	abstract[247]	new[247]	_	_
21-2	3874-3882	COLUMBUS	place|abstract[247]	giv|new[247]	_	_
21-3	3883-3888	study	abstract[247]	new[247]	_	_
21-4	3889-3892	was	_	_	_	_
21-5	3893-3901	utilized	_	_	_	_
21-6	3902-3904	as	_	_	_	_
21-7	3905-3906	a	_	_	_	_
21-8	3907-3913	source	_	_	_	_
21-9	3914-3916	of	_	_	_	_
21-10	3917-3927	additional	abstract[248]	giv[248]	_	_
21-11	3928-3939	information	abstract[248]	giv[248]	_	_
21-12	3940-3943	for	abstract[248]	giv[248]	_	_
21-13	3944-3951	adverse	abstract[248]|event[249]	giv[248]|new[249]	_	_
21-14	3952-3958	events	abstract[248]|event[249]	giv[248]|new[249]	_	_
21-15	3959-3962	for	abstract[248]|event[249]	giv[248]|new[249]	_	_
21-16	3963-3966	the	abstract[248]|event[249]|substance[250]	giv[248]|new[249]|giv[250]	_	_
21-17	3967-3978	encorafenib	abstract[248]|event[249]|substance[250]	giv[248]|new[249]|giv[250]	_	_
21-18	3979-3983	plus	abstract[248]|event[249]|substance[250]	giv[248]|new[249]|giv[250]	_	_
21-19	3984-3995	binimetinib	abstract[248]|event[249]|substance[250]|object|abstract[252]	giv[248]|new[249]|giv[250]|giv|giv[252]	_	_
21-20	3996-4007	combination	abstract[248]|event[249]|substance[250]|abstract[252]	giv[248]|new[249]|giv[250]|giv[252]	_	_
21-21	4008-4009	.	_	_	_	_
